Trials / Unknown
UnknownNCT04930458
Remineralization of Dentine Caries Using Two Remineralizing Agents Which Are Nanosilver Fluoride and Casein phosphopeptides_amorphous Calcium Phosphate
Remineralization of Dentine Caries Using Nanosilver Fluoride and Casein Phosphopeptides-amorphous Calcium Phosphate (A Randomized Clinical Trial)
- Status
- Unknown
- Phase
- N/A
- Study type
- Interventional
- Enrollment
- 135 (estimated)
- Sponsor
- University of Baghdad · Academic / Other
- Sex
- All
- Age
- 6 Years – 12 Years
- Healthy volunteers
- Accepted
Summary
The study is randomized controlled trial ...The null hypothesis suggests that there is no significant difference between nanosilver fluoride and sodium fluoride with Casein phosphopeptides\_amorphous calcium phosphate in the remineralization of dental caries.
Detailed description
the patients will be randomly assigned to one of three study groups the first group is nanosilver fluoride,the second is casein phosphopeptides\_amorphous calcium phosphate and the third is sodium fluoride as positive control..the three material will be applied in single application with no repetition ..follow up after one and three month ..the patient should have at least one carious lesion(ICDASII code 5)
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| OTHER | Nanosilver fluoride | Nanosilver fluoride will be applied to the affected tooth in single application and then follow up after one and three months |
| OTHER | Sodium fluoride with casein phosphopeptides amorphous calcium phosphate | Sodium fluoride with casein phosphopeptides amorphous calcium phosphatewill be applied to the affected tooth in single application and then follow up after one and three months |
| OTHER | Sodium fluoride varnish | Sodium fluoride varnish will be applied to the affected tooth in single application and then follow up after one and three months |
Timeline
- Start date
- 2021-08-10
- Primary completion
- 2021-09-20
- Completion
- 2022-06-20
- First posted
- 2021-06-18
- Last updated
- 2022-05-17
Locations
1 site across 1 country: Iraq
Source: ClinicalTrials.gov record NCT04930458. Inclusion in this directory is not an endorsement.